DRZ

As a follow up to the article that appeared in Forbes magazine, Blood, the world’s leading haematology magazine, has published an article by Dr. Steve Treon. In the article, Dr. Treon explains the logic and process of ibrutinib’s possible effect on COVID-19. We have provided a .pdf of the article here. Of extra interest to WMFC members is the reference to the transgenic mouse model which has been through two stages of research that the WMFC has funded and supported with Dr. Treon at the Dana Farber Cancer Institute over the last five or six years. .PDF of Dr. Treon's [...]

On Dec. 2, 2020, the Support Group leaders from across the US and Canada got together over Zoom.  There are three sections to the video.  The most important is the following one, given the current Covid situation: From approximately the 22 minute mark to the 34 minute point, Dr. Castillo of the Dana-Farber Bing Center discusses the leading Covid-19 candidates, and his take on their safety and efficacy in WM patients. The other two sections of the video include: From approximately 36:50 to 42:00, there is a discussion of topics presented at the recent ASH 2020 conference (American Society of [...]

Consensus Statement Published August, 2020 In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel has published a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time. The Panel followed the current recommendations by the American Society of Hematology, which have been modified accordingly to fit the specific realities associated with the management of WM. The Panel addressed questions related to treatment initiation, preferred therapies, minimizing visit to clinics and infusions centers, supportive care and guidance for WM patients in clinical trials. It also provided information on timing [...]